MX2024005742A - Compuestos de acidos nucleicos modificados con lipidos triples escalonados. - Google Patents

Compuestos de acidos nucleicos modificados con lipidos triples escalonados.

Info

Publication number
MX2024005742A
MX2024005742A MX2024005742A MX2024005742A MX2024005742A MX 2024005742 A MX2024005742 A MX 2024005742A MX 2024005742 A MX2024005742 A MX 2024005742A MX 2024005742 A MX2024005742 A MX 2024005742A MX 2024005742 A MX2024005742 A MX 2024005742A
Authority
MX
Mexico
Prior art keywords
nucleic acid
lipid
acid compounds
modified nucleic
triple
Prior art date
Application number
MX2024005742A
Other languages
English (en)
Spanish (es)
Inventor
Arthur T Suckow
Charles Allerson
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2024005742A publication Critical patent/MX2024005742A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
MX2024005742A 2021-11-15 2022-11-14 Compuestos de acidos nucleicos modificados con lipidos triples escalonados. MX2024005742A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163279270P 2021-11-15 2021-11-15
PCT/US2022/079790 WO2023086979A1 (en) 2021-11-15 2022-11-14 Staggered triple lipid-modified nucleic acid compounds

Publications (1)

Publication Number Publication Date
MX2024005742A true MX2024005742A (es) 2024-05-27

Family

ID=86336682

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024005742A MX2024005742A (es) 2021-11-15 2022-11-14 Compuestos de acidos nucleicos modificados con lipidos triples escalonados.

Country Status (10)

Country Link
US (1) US20250027082A1 (cg-RX-API-DMAC10.html)
EP (1) EP4433064A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024543372A (cg-RX-API-DMAC10.html)
KR (1) KR20240103016A (cg-RX-API-DMAC10.html)
CN (1) CN118215484A (cg-RX-API-DMAC10.html)
AU (1) AU2022387688A1 (cg-RX-API-DMAC10.html)
CA (1) CA3235447A1 (cg-RX-API-DMAC10.html)
IL (1) IL312217A (cg-RX-API-DMAC10.html)
MX (1) MX2024005742A (cg-RX-API-DMAC10.html)
WO (1) WO2023086979A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026163078A1 (en) 2025-01-29 2026-08-06 Novartis Ag Compounds targeting dmpk for the treatment of myotonic dystrophy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7583712B2 (ja) * 2018-05-30 2024-11-14 ノバルティス アーゲー 脂質修飾された核酸化合物および方法
JP2023503644A (ja) * 2019-11-27 2023-01-31 ディー・ティー・エックス・ファーマ・インコーポレイテッド デュシェンヌ型筋ジストロフィーの治療のための化合物および方法

Also Published As

Publication number Publication date
US20250027082A1 (en) 2025-01-23
CN118215484A (zh) 2024-06-18
JP2024543372A (ja) 2024-11-21
EP4433064A4 (en) 2026-07-22
KR20240103016A (ko) 2024-07-03
AU2022387688A1 (en) 2024-04-11
IL312217A (en) 2024-06-01
CA3235447A1 (en) 2023-05-19
EP4433064A1 (en) 2024-09-25
WO2023086979A1 (en) 2023-05-19

Similar Documents

Publication Publication Date Title
GB2603704B (en) Class II, type V Crispr systems
GB2608292B (en) Class II, type II CRISPR systems
MY197889A (en) Microorganism producing l-amino acid and method for producing l-amino acid using the same
CA3262976A1 (en) CRISPR TYPE V, CLASS II SYSTEMS
MX2022007696A (es) Celulas de levadura y metodos para la produccion de e8,e10-dodecadienil coenzima a, codlemona y derivados de las mismas.
WO2023081762A3 (en) Serine recombinases
EP4049126A4 (en) ELECTROGRAM ANNOTATION SYSTEM
EP4063485A4 (en) ELECTRON CARRIER, METHOD OF MAKING AN ELECTRON CARRIER AND METHOD OF ELECTRON TRANSFER
PH12021550883A1 (en) Crystalline salts of a plasma kallikrein inhibitor
EP4178971A4 (en) RNA scaffolds
EP4065553A4 (en) NEW COMPOUND, METHOD FOR PREPARATION AND USE
WO2023086978A3 (en) Branched triple lipid-modified nucleic acid compounds
EP3970793A4 (en) MEANS OF PREVENTING, IMPROVING OR TREATMENT OF PERIODONTAL DISEASES
MX2025008767A (es) Compuestos triciclicos sustituidos
WO2021086973A3 (en) Formulation for delivery of lubricin gene
WO2004047763A3 (en) Production of ubiquinones
CA3305153A1 (en) Antiviral 1,3-di-oxo-indene compounds
HK40111861A (en) Staggered triple lipid-modified nucleic acid compounds
WO2021007502A3 (en) Differential knockout of a heterozygous allele of rpe65
MX2021012690A (es) Formas cristalinas y metodos para producir formas cristalinas de un compuesto.
HK40101427A (en) Class ii, type v crispr systems
HK40102637A (en) Class ii, type v crispr systems
HK40086587A (en) Class ii, type v crispr systems
HK40077389B (en) Class ii, type v crispr systems
EP3978024A4 (en) Production method for bifurcated lipid-linked oligonucleotide, and intermediate